SWX:COPN
SWX:COPNPharmaceuticals

Unveiling November 2025's Undiscovered Gems in Europe

As European markets navigate the complexities of cooling sentiment on artificial intelligence and mixed economic indicators, the pan-European STOXX Europe 600 Index has managed to rise by 1.77%, buoyed by relief over the U.S. federal government reopening. In this environment, identifying promising small-cap stocks requires a keen eye for companies that demonstrate resilience and adaptability amid fluctuating market conditions, particularly those with robust fundamentals that can weather...
SWX:NOVN
SWX:NOVNPharmaceuticals

Novartis (SWX:NOVN): Assessing Shareholder Value After Recent Downtrend

Novartis (SWX:NOVN) shares recently edged lower, continuing a slight downtrend seen over the past week and month. Investors are now weighing the implications of these moves in relation to the company’s track record and recent financial performance. See our latest analysis for Novartis. Even with Novartis’s recent slip, the bigger picture looks resilient, with a steady year-to-date share price return of nearly 13 percent and a strong 1-year total shareholder return of 13.6 percent. While...
SWX:SIKA
SWX:SIKAChemicals

How Investors Are Reacting To Sika (SWX:SIKA) Securing CHF 600 Million in Multi-Tranche Bonds

Sika has successfully completed the placement of CHF 600 million in bonds across three tranches, with maturities spanning from 2027 to 2034 and yields ranging from 0.45% to 1.16%, which will be listed on the SIX Swiss Exchange. This multi-tranche bond issuance was designed to optimize Sika’s funding structure and enhance financial flexibility by lowering overall group-wide funding costs. We’ll explore how Sika’s strengthened funding profile may influence its investment narrative and future...
SWX:ROG
SWX:ROGPharmaceuticals

Roche Holding (SWX:ROG) Is Up 7.6% After Key Drug Approvals and Oncology Collaboration – What's Changed

In the past week, Roche announced a series of major developments, including the European Commission's conditional approval of Lunsumio subcutaneous for relapsed/refractory follicular lymphoma, positive phase III results for fenebrutinib in multiple sclerosis, and a new clinical trial collaboration with KaliVir Immunotherapeutics to advance novel combination immunotherapies in oncology. These milestones highlight Roche's continued expansion across oncology and neurology, with new treatment...
SWX:AVOL
SWX:AVOLSpecialty Retail

Avolta (SWX:AVOL): Assessing Valuation After Strategic Moves in Asia Pacific Travel Retail

Avolta (SWX:AVOL) is making moves across the Asia Pacific, entering Japan’s Kansai Airport with new retail ideas and debuting refreshed stores in Perth. The company’s latest loyalty partnership in Thailand also signals deeper customer engagement. See our latest analysis for Avolta. While Avolta’s latest moves in Japan, Australia, and Thailand have made headlines, the market story goes deeper. The stock’s year-to-date share price return sits at an impressive 18.96%, and the one-year total...
SWX:BARN
SWX:BARNFood

Barry Callebaut (SWX:BARN): Unpacking Valuation on Goldman Sachs Buy Rating and Turnaround Signals

Barry Callebaut (SWX:BARN) stock came into focus after Goldman Sachs initiated coverage with a Buy rating, signaling increased attention from market participants. This move suggests broader confidence in the company’s mid-term prospects and ongoing transformation. See our latest analysis for Barry Callebaut. Momentum has started to build for Barry Callebaut, with its strategic partnership with NotCo AI and a recently affirmed dividend highlighting its transformation agenda. While the 90-day...
SWX:ABBN
SWX:ABBNElectrical

Is ABB (SWX:ABBN) Prioritizing Margin Over Growth in Its Latest Guidance Update?

At the Bloomberg New Economy Forum in Singapore, ABB recently reaffirmed its mid-term revenue growth target of 5–7% annually on a comparable basis and raised its operational earnings margin goal to 18–22%. While the increased profitability target marked a positive step, the decision not to lift sales growth guidance, despite stronger targets from peers, stood out to industry observers and investors. We'll examine how ABB's decision to maintain its sales growth target, even as peers raise...
SWX:UBXN
SWX:UBXNSemiconductor

Does u-blox Holding's (SWX:UBXN) Index Exit Reveal Shifts in Its Investor Appeal?

On November 18, 2025, u-blox Holding AG (SWX:UBXN) was removed from the S&P Global BMI Index, a widely tracked global benchmark for equities. This index exclusion can influence trading behavior, as passive funds often adjust their portfolios to align with index changes, potentially impacting liquidity. We'll now consider how the index removal and subsequent fund adjustments may shape u-blox Holding's broader investment narrative. We've found 15 US stocks that are forecast to pay a dividend...
SWX:SENS
SWX:SENSElectronic

High Growth Tech Stocks to Watch in November 2025

As global markets navigate the aftermath of the longest U.S. government shutdown in history, investors are observing mixed performances across major indices, with small-cap stocks particularly underperforming due to heightened sensitivity to interest rate movements and ongoing concerns about elevated valuations. In this environment, identifying high-growth tech stocks requires a focus on companies that can demonstrate resilience and adaptability amid economic uncertainties and shifting market...
SWX:GALD
SWX:GALDPharmaceuticals

Is Galderma's New Restylane Lyft Data and FDA Approval Reshaping Its Competitive Edge (SWX:GALD)?

Galderma recently presented new clinical data from its Restylane and Sculptra portfolios at the American Society for Dermatologic Surgery 2025 Annual Meeting in Chicago, including results that supported the recent FDA approval of Restylane Lyft for chin augmentation in adults. This new data not only highlights high patient satisfaction and durable results for the company’s injectable aesthetics but also addresses emerging needs among patients experiencing facial changes following...
SWX:GALE
SWX:GALEHealthcare

What Galenica (SWX:GALE)'s CHF 250 Million Bond Issuance Means For Shareholders

Earlier this month, Galenica AG announced the successful placement of a CHF 250 million fixed rate bond with a 7-year term and a 1.08% annual coupon, set to mature in 2032 and managed by UBS. This move enables Galenica to refinance bridge financing from its Labor Team Group acquisition, lowers short-term liabilities, and further strengthens its long-term capital structure. We will now examine how extending Galenica’s debt maturity profile through this bond may influence the company’s...